Ref ENTA: The $83,319 cost is neither appealing to the investor eye nor to the PAYER (insurance). It was essential, bordering on CRITICAL that pricing was correct for the PAYER. ABBV couldnt have gotten it any more incorrect. ANY price in the mid-$70K's was the sweet spot (psychology view). Little price erosion ultimately... and considerable MS uptake. I am disappointed at the lack of thought....
No difference to ENTA over time but short sighted really.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.